Natera publishes new clinical validation of Signatera for lymphoma MRD
Natera said new data published in Blood Neoplasia validates the prognostic and predictive value of Signatera for MRD assessment in newly diagnosed and relapsed/refractory lymphoma patients.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma.PET/CT scans…